NASDAQ:CCCC C4 Therapeutics Q3 2024 Earnings Results & Report $2.78 -0.28 (-9.15%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$2.85 +0.07 (+2.37%) As of 10/13/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. C4 Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2024 results, released October 31, 2024. The company reported EPS of -$0.35 versus the -$0.40 consensus estimate, while revenue of $15.36 million topped the $5.95 million estimate by $9.41 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateOctober 31, 2024TimeBefore Market OpensConference Call7:00 AM ET C4 Therapeutics EPS ResultsActual EPS-$0.35Consensus EPS -$0.40Beat/MissBeat by +$0.05One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersC4 Therapeutics Revenue ResultsActual Revenue$15.36 millionExpected Revenue$5.95 millionBeat/MissBeat by +$9.41 millionYoY Revenue GrowthN/AUpcoming EarningsC4 Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) C4 Therapeutics Q3 2024 Earnings FAQ Did C4 Therapeutics beat earnings estimates for Q3 2024? C4 Therapeutics (NASDAQ:CCCC) reported earnings of -$0.35 per share for Q3 2024, beating the consensus estimate of -$0.40. The report was announced on Thursday, October 31, 2024. What was C4 Therapeutics' revenue for Q3 2024? C4 Therapeutics reported revenue of $15.36 million for Q3 2024, against a consensus estimate of $5.95 million. When is C4 Therapeutics' next earnings date? C4 Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for C4 Therapeutics on the company's earnings history page. C4 Therapeutics Earnings HeadlinesC4 Therapeutics (NASDAQ:CCCC) Stock Picked Up by Analysts at JPMorgan Chase & Co.October 11 at 1:30 AM | americanbankingnews.comCoya Therapeutics (NASDAQ:COYA) and C4 Therapeutics (NASDAQ:CCCC) Financial ReviewOctober 6, 2026 | americanbankingnews.comMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. | Crypto 101 Media (Ad)Comparing Immatics (NASDAQ:IMTX) & C4 Therapeutics (NASDAQ:CCCC)October 3, 2026 | americanbankingnews.comCemsidomide Shows Immune Activation In C4 Therapeutics' Myeloma StudySeptember 26, 2026 | rttnews.comC4 Therapeutics, Inc. Presents New Biomarker Data from Cemsidomide Phase 1 Trial With Dexamethasone and Phase 1b Trial With Elranatamab in Relapsed/Refractory Multiple MyelomaSeptember 25, 2026 | marketscreener.comMSee More C4 Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like C4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on C4 Therapeutics and other key companies, straight to your email. Email Address About C4 TherapeuticsC4 Therapeutics (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses targeted protein degradation, an approach designed to direct the body’s natural cellular machinery to identify and remove specific proteins that contribute to cancer and other diseases. C4 Therapeutics’ proprietary TORPEDO platform is used to discover and develop small-molecule protein degraders. Its research and development programs have included therapies aimed at targets implicated in blood cancers, solid tumors and genetically defined cancers, including programs directed at IKZF1/3, BRD9 and mutant BRAF. The company has also pursued collaborations intended to apply targeted protein degradation to additional therapeutic areas. Founded in 2015, C4 Therapeutics is headquartered in Watertown, Massachusetts. The company conducts its research primarily in the United States and has worked with international pharmaceutical partners to advance selected discovery and development programs. Andrew J. Hirsch serves as president and chief executive officer.View C4 Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
